Trial Profile
An Open Label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs PT 2385 (Primary)
- Indications Renal cell carcinoma; Von Hippel-Lindau disease
- Focus Therapeutic Use
- Sponsors Peloton Therapeutics
- 18 Dec 2023 Status changed from active, no longer recruiting to completed.
- 13 Jul 2022 Planned End Date changed from 15 Jun 2022 to 30 Nov 2023.
- 13 Jul 2022 Planned primary completion date changed from 15 Jun 2022 to 30 Nov 2023.